Prelude Therapeutics (PRLD) FCF Margin (2024 - 2026)

Prelude Therapeutics (PRLD) posted FCF Margin of 473.47% for Q1 2026, down 215.51% sequentially from 409.91% in Q4 2025.

Prelude Therapeutics (PRLD) FCF Margin (2024 - 2026) Analysis & Trends

Prelude Therapeutics has reported FCF Margin for 3 years, with the latest figure at 473.47% in Q1 2026.

Quarterly FCF Margin changed N/A year-over-year to 473.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 261.82% (changed N/A YoY) and the FY2025 annual result came in at 464.32%, up 100565.0% from the prior year.
FCF Margin eased to 473.47% in Q1 2026 per PRLD's latest filing, from 409.91% in the prior quarter.
Over five years, FCF Margin peaked at 409.91% in Q4 2025 and troughed at 911.97% in Q3 2024.
A 3-year average of 354.14% and a median of 473.47% in 2026 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 91099 bps in 2025, down 61789 bps in 2025.
Over 3 years, FCF Margin stood at 501.08% in 2024, then soared by 182 bps to 409.91% in 2025, then plunged by 216 bps to 473.47% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 473.47%, 409.91%, and 294.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	Prelude Therapeutics	442.91 Mn	162.28 Mn	-	-273.53%

Download Data